Do Research Peptides Need Refrigeration? Cold Chain, Customs and Carriers
The published stability data say lyophilised material is far more robust in transit than the ice packs imply, the real thermal risk sits in customs hold rather than scheduled transit, and dry ice is more dangerous to material in solution than an ambient excursion is.
Two questions dominate every enquiry about research peptide supply: will it clear customs, and will it survive the journey. Behind the second sits a narrower one — do research peptides need refrigeration in transit at all, or is the ice pack theatre? The honest answers are more interesting than the marketing. One of them contradicts an industry convention that almost every supplier repeats, this one included.
The Stability Science
The best-characterised published data point comes from a 2026 study of thermally stressed solid-state semaglutide. Using FT-IR, circular dichroism, modulated DSC, RP-HPLC and LC-HRMS, the authors found the material retains its native α-helical conformation up to 60 °C, with helical content falling from 49.07% to 43.75% at 60 °C and collapsing to 0.2% at 80 °C. The amorphous solid has a glass transition temperature of 169 °C.
That figure is the crux. Below its glass transition the matrix is a rigid glass, and molecular mobility — and therefore the hydrolysis, deamidation and aggregation that destroy peptides — is kinetically suppressed. A parcel sitting at 35 °C in a Dubai delivery van is roughly 134 °C below Tg. The temperature that genuinely threatens a lyophilised peptide is not shipping ambient; it is the 60–80 °C range where secondary structure collapses. The same paper still reports temperature-dependent degradation, so robust does not mean unaffected — but the order of magnitude is not what cold-chain marketing implies.
The mechanism is chemistry rather than folklore: deamidation, the dominant degradation route for peptides containing asparagine or glutamine, is water-mediated. Lyophilisation removes the reactant. A dry cake is slow, not inert.
What the Innovators’ Own Labels Permit
The most persuasive evidence is what manufacturers submitted to regulators about their own products. Ozempic’s FDA label §16 states that after first use the pen can be stored for 56 days at controlled room temperature, 15–30 °C. Mounjaro, per its SmPC, may be stored unrefrigerated for up to 30 days at a temperature not above 30 °C after first use.
These are aqueous, preservative-containing solutions — the physically less stable form — and the regulatory dossier permits a month at 30 °C. They are in-use allowances following an unbroken cold chain, not licence to ship warm, but they establish the scale. A two to four day air transit at ambient is not the event that degrades the molecule.
A useful real-world analogue: a 2021 PLOS ONE study placed insulin under temperature profiles logged in a refugee camp in northern Kenya, oscillating between 25 °C and 37 °C. Weekly HPLC showed conformity to pharmacopoeial guidelines across four weeks, and bioactivity in hepatic cells was identical to material held at 2–8 °C.
The Asymmetry That Actually Matters: Do Not Freeze
Both labels above carry the same instruction, and it points the opposite way to intuition: do not freeze, and do not use if it has been frozen. Freezing damages peptide solutions through ice-interface denaturation and freeze-concentration.
This produces the most counter-intuitive conclusion in this article: for any peptide shipped in solution rather than as a lyophilised solid, dry ice poses a greater risk to the material than an ambient excursion does.
For context on what the industry considers a punishing thermal challenge, ICH Q1A(R2) sets the accelerated stability condition at 40 °C and 75% relative humidity for six months. A 72-hour transit is not in the same universe. ICH also supplies the right tool for assessing an excursion — mean kinetic temperature, weighted by the Arrhenius equation — and published modelling shows excursions consume a stability budget rather than producing a binary pass or fail.
So What Does Cold-Chain Dispatch Actually Buy
- Protection against tail risk. Not the scheduled transit, but the parcel forgotten in a sorting hub or standing on a Gulf tarmac where surface temperatures reach the range that does matter.
- Documentary evidence of controlled conditions. A quality-system artefact under Good Distribution Practice, which is a real and separate value.
- Signal — which is legitimate, provided it is not dressed as the first two.
What it does not buy, on any evidence located: preserved potency that would otherwise be lost over 48–72 hours of ambient transit in a lyophilised product. The genuine dividing line is solid versus solution, not cold versus warm. Lyophilised powder in short transit is a minor thermal event; its real risks are moisture ingress — a stopper and seal problem, not an ice pack problem — and sustained heat above 60 °C. In solution, water is present, degradation chemistry proceeds, and freezing becomes a distinct failure mode. That is where controlled 2–8 °C storage genuinely earns its place: in qualified cold storage at the receiving facility, not in the carrier’s network.
Standards and Carriers
EU Good Distribution Practice (2013/C 343/01), Chapter 9 governs transport and is applied by the MHRA. Its principle: regardless of mode, it should be possible to demonstrate that the medicines have not been exposed to conditions that may compromise their quality and integrity. Three requirements are worth quoting because they are frequently ignored — container selection must account for the estimated maximum time for transportation including transit storage at customs; monitoring equipment must be calibrated at least once a year; and if cool-packs are used in insulated boxes they must be located so the product does not come into direct contact with the cool-pack.
WHO TRS 961 Annex 9 sets container qualification expectations: a qualified passive system must demonstrate it can hold the required range, documenting the packaging assembly, conditioning regime and the minimum and maximum shipping volume and thermal mass it accommodates. Data loggers should be accurate to ±0.5 °C, recording at least six times per hour. On excursions, affected product is to be quarantined and evaluated, not automatically discarded. ISTA 7E profiles, developed from real-world data across 82 shipping lanes, are published in 72-hour and 144-hour variants.
One gap worth stating: no neutral, non-commercial source publishes comparative hold times for gel packs versus dry ice versus phase-change materials. Every such figure originates from a packaging manufacturer marketing its own product. WHO TRS 961 treats coolants as ancillary packaging with no independent duration requirement — performance is only ever established by qualifying the complete system.
Dry ice is a regulatory event. Under IATA Packing Instruction 954 it is UN 1845, Class 9 dangerous goods: packaging must vent to prevent pressure build-up, the outer must be marked with UN 1845, the proper shipping name and net weight in kilograms and carry a Class 9 label, the air waybill needs a specific entry, and shippers require IATA or DOT training renewed every two years. Combined with the freezing prohibition above, the conclusion is clean: dry ice is the wrong coolant for peptide product in almost every commercial scenario. It adds a dangerous-goods burden and introduces a failure mode.
A caution on carriers: none of the major integrators publishes a pharmaceutical acceptance rule. DHL routes such questions to a restricted commodities team; UPS accepts certain categories on a contractual basis only. Acceptance here is a commercial relationship, not a public standard.
The UK Border
The classification framework — the two-limb medicinal product test under the Human Medicines Regulations 2012, the supply prohibitions in regulations 46 and 255, and the penalties in regulation 47 — is covered in full in our UK legal status guide. Two points specific to physically moving goods across the border are worth adding, because both are routinely reported wrongly.
Customs classification saves nothing fiscally. Duty on peptide hormones into the UK is zero. Commodity heading 2937 — which expressly covers chain modified polypeptides used primarily as hormones — attracts 0.00% third-country duty and 20% import VAT. Laboratory reagents under 3822 also attract 0% duty and 20% VAT. Declaring under a reagent code therefore changes no tax outcome whatsoever; the only variable it moves is the regulatory flag attached to the commodity code, which makes misclassification a customs exposure rather than a tax strategy. Separately, VAT liability shifts at £135 consignment value.
The controlled-drug trap. Most research peptides — BPC-157, TB-500, ipamorelin, CJC-1295, sermorelin, tesamorelin, melanotan — are not controlled under the Misuse of Drugs Act 1971. But somatropin, somatotropin, somatrem and human chorionic gonadotrophin are Class C controlled drugs, added by the 1996 Modification Order. There is no simple possession offence for Schedule 4 Part II drugs, but a 2012 amendment narrowed the import exemption to importation carried out in person for administration to that person. A courier parcel is not "in person". Mail-ordering somatropin or hCG into the UK is therefore an importation offence, not merely a medicines-regulation breach — a change made in 2012 and still reported incorrectly across most of the industry.
The UAE Border
A free zone sits outside the import perimeter by definition. The governing law defines import as bringing products from outside the country or its free zones to the mainland. A free-zone entity can therefore hold and re-export stock without it ever having been imported; the regulatory event occurs at the moment goods cross into the mainland, which requires marketing approval and an import permit. A free-zone licence is not market access, and it is not a workaround for product registration. Note also that the scope of licensable establishments expressly includes research entities, contract research organisations, pharmaceutical laboratories and biobanks — describing an activity as research does not remove it from the licensing regime, it places it inside a different part of it.
On customs specifically: Abu Dhabi Customs lists pharmaceutical preparations and medicines, medical devices, accessories, laboratory solutions and sterilization devices as restricted and requiring health-ministry approval — the closest official UAE text to research-reagent classification, and notable because it routes lab solutions through the health regulator by default rather than a general chemicals regime. Dubai Customs applies 5% duty on CIF value and prohibits bulk quantities for personal use without special permission.
What This Adds Up To
Transit duration is not the binding constraint on a UK–UAE lane. Against in-use ambient allowances measured in weeks and a solid-state glass transition at 169 °C, a two to four day express transit is thermally trivial. The binding constraints are customs hold time — unbounded, and expressly called out in EU GDP as a factor in container selection — and peak temperature in sorting hubs and on tarmac, neither of which is a function of how fast the plane flies.
The regulatory constraints are the real ones, and they are not symmetrical: the UK question is medicines classification and the controlled-drug carve-outs; the UAE question is mainland entry, registration and the free-zone boundary. Neither is solved by a label, and neither is solved by an ice pack.
Research use only. PepcoLab compounds are supplied for laboratory and in-vitro research purposes. They are not approved for human or veterinary use, consumption, or household purposes. This article addresses material handling and regulatory logistics; it is not guidance on administration, and a research-use designation does not authorise human use.